---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-023671"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:41:56.347149+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics reports Phase 1 data for FHD-286 in uveal melanoma, will not advance independently

## Summary
- Phase 1 dose escalation study of FHD-286 in 73 metastatic uveal melanoma patients showed safety and tolerability; most common adverse events were dysgeusia, fatigue, AST increase.
- One patient achieved durable partial response (>16 months on treatment), nine patients had stable disease, and tumor reductions were observed in eight patients.
- Company will not advance FHD-286 in uveal melanoma; plans to initiate combination study with decitabine or cytarabine in relapsed/refractory AML in Q3 2023.
- Preliminary immune modulation markers in tumor microenvironment support combination with checkpoint inhibitors; full results to be presented at future scientific meeting.

## SEC filing metadata
- accession: 0001628280-23-023671
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023023671/0001628280-23-023671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023023671/fhtx-20230628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-023671
- JSON: https://secwatch.observer/filing/0001628280-23-023671.json
- Plain text: https://secwatch.observer/filing/0001628280-23-023671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.